Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases

Huang, Yingna; Yang, Lina

doi:10.1186/s13287-021-02289-7

Cited by 37 publications

(31 citation statements)

References 121 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar abilities of EVs to counteract with apoptosis have been recently confirmed also in the model of AKI induced by ischemic reperfusion injury (IRI) [16,49].…”

Section: The Anti-apoptotic Effect Of Evs During Aki Treatmentsupporting

confidence: 53%

Extracellular vesicles derived from mesenchymal stem cells as a potential therapeutic agent in acute kidney injury (AKI) in felines: review and perspectives

Kraińska

Pietrzkowska²,

Turlej

et al. 2021

Stem Cell Res Ther

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), known from their key role in the regeneration process of tissues, and their abilities to release bioactive factors like extracellular vesicles (EVs) could be considered as a potential, modern tool in the treatment of AKI (acute kidney injury) in both human and veterinary patients. The complex pathophysiology of a renal function disorder (AKI) makes difficult to find a universal therapy, but the treatment strategy is based on MSCs and derived from them, EVs seem to solve this problem. Due to their small size, the ability of the cargo transport, the ease of crossing the barriers and the lack of the ability to proliferate and differentiate, EVs seem to have a significant impact on the development such therapy. Their additional impact associated with their ability to modulate immune response and inflammation process, their strong anti-fibrotic and anti-apoptotic effects and the relation with the releasing of the reactive oxygen species (ROS), that pivotal role in the AKI development is undoubtedly, limits the progress of AKI. Moreover, the availability of EVs from different sources encourages to extend research with using EVs from MSCs in AKI treatment in felines; in that, the possibilities of kidney injuries treatment are still limited to the classical therapies burdened with dangerous side effects. In this review, we underline the significance of the processes, in whose EVs are included during the AKI in order to show the potential benefits of EVs-MSCs-based therapies against AKI in felines.

show abstract

“…Similar abilities of EVs to counteract with apoptosis have been recently confirmed also in the model of AKI induced by ischemic reperfusion injury (IRI) [16,49].…”

Section: The Anti-apoptotic Effect Of Evs During Aki Treatmentsupporting

confidence: 53%

Extracellular vesicles derived from mesenchymal stem cells as a potential therapeutic agent in acute kidney injury (AKI) in felines: review and perspectives

Kraińska

Pietrzkowska²,

Turlej

et al. 2021

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…In a cohort of adult patients with AKI after cardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of kidney function. MSC-derived extracellular vesicles have the advantages of lower immunogenicity and tumorigenicity; their clinical use is currently being explored [19].…”

Section: Alterations In Tubule Cell Proliferationmentioning

confidence: 99%

Pathogenesis of intrinsic acute kidney injury

Devarajan

2022

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of reviewThis review focuses on the pathogenesis of intrinsic acute kidney injury (AKI), emphasizing recent advances that hold therapeutic promise.Recent findingsEnhanced endothelin and reduced endothelium-derived nitric oxide release in AKI can be blocked using endothelin receptor antagonists or nitric oxide supplementation. Vasodilatory agents such as theophylline and caffeine may prevent AKI. Free labile iron is a potent factor in the generation of reactive oxygen species and tubule damage in AKI. Apoptosis via induction of p53 is an important mechanism of cell death in AKI, which can be blocked using small interfering RNA. The AKI-driven reduction in nicotinamide adenine dinucleotide can be countered using oral supplements. Surviving tubule cells regenerate after AKI, by upregulating genes encoding growth factors, such as hepatocyte growth factor. Pro-angiogenic agents (statins and erythropoietin) that can mobilize endothelial progenitor cells after AKI are currently being tested. The inflammatory response in AKI, including activation of C5a, can be therapeutically targeted. Contemporary single cell profiling technologies have identified novel genes with altered expression, new signalling pathways and drug targets in AKI.SummaryRecent advances in the pathogenesis of intrinsic AKI have provided a better understanding of the clinical continuum and the rational deployment of promising therapeutics.

show abstract

“…Moreover, EVs isolated from MSCs are promising strategies in kidney diseases, as they modulate several biological processes, such as oxidative stress, apoptosis, inflammation, fibrosis, angiogenesis, cell cycle, regeneration, autophagy and cell proliferation [235,236].…”

Section: Properties and Characterization Of Mesenchymal Stem Cellsmentioning

confidence: 99%

Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease

2021

View full text Add to dashboard Cite

Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems, and their prevalence rates have increased with the aging of the population. They are associated with the presence of comorbidities, in particular diabetes mellitus and hypertension, resulting in a high financial burden for the health system. Studies have indicated Klotho as a promising therapeutic approach for these conditions. Klotho reduces inflammation, oxidative stress and fibrosis and counter-regulates the renin-angiotensin-aldosterone system. In CKD and AKI, Klotho expression is downregulated from early stages and correlates with disease progression. Therefore, the restoration of its levels, through exogenous or endogenous pathways, has renoprotective effects. An important strategy for administering Klotho is through mesenchymal stem cells (MSCs). In summary, this review comprises in vitro and in vivo studies on the therapeutic potential of Klotho for the treatment of CKD and AKI through the administration of MSCs.

show abstract

Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases

Cited by 37 publications

References 121 publications

Extracellular vesicles derived from mesenchymal stem cells as a potential therapeutic agent in acute kidney injury (AKI) in felines: review and perspectives

Extracellular vesicles derived from mesenchymal stem cells as a potential therapeutic agent in acute kidney injury (AKI) in felines: review and perspectives

Pathogenesis of intrinsic acute kidney injury

Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease

Contact Info

Product

Resources

About